What Lotus Clinical Research does

Lotus Clinical Research is a US-based, privately held contract research organization (CRO) founded in 2014 and headquartered in Edison, New Jersey, specializing in clinical development for neuroscience (psychiatry, pain, neurology, neuropsychiatry, addiction) and metabolic (obesity, diabetes, MASH) indications. The company delivers full-service Phase I–IV trial capabilities — project management, clinical monitoring, medical monitoring, EDC/data management, biostatistics, PK/PD modeling, and quality operations — augmented by a portfolio of proprietary scientific solutions: Global Rater Training & Certification (30+ years, 30+ countries), the Placebo Response Mitigation (PRM) program (deployed in 50+ studies), the Unified Site Methodology (USM) program, and centralized Eligibility Review. Summit Analytical, a wholly-owned division, provides specialized biostatistics, statistical programming, and PK/PD modeling, while the NeuroKit CNS testing platform (exclusive US partnership with CHDR, launched October 2025) extends Lotus's early-phase pharmacodynamic assessment capabilities.

The company's defining structural advantage is common ownership with Evolution Research Group (ERG), which gives it priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units in Miami (CPMI) and Columbus (OCT). This integrated CRO-site model shortens contracting, legal, and startup timelines and is positioned as the company's primary differentiator versus standalone CROs. The technology stack combines Veeva Vault Clinical Suite (EDC, CTMS, eTMF), ETQ Reliance QMS, Trialogics clinical trial software, and validated Phoenix WinNonlin for PK analysis; databases are 21 CFR Part 11 and CDISC-compliant and aligned with ICH-E6(R3) GCP standards.

Lotus operates a B2B enterprise sales model, engaging pharmaceutical and biotechnology sponsors through an RFP/bid process with scientific leadership review at the bid stage and dedicated business development through study execution. Revenue is generated through custom-quoted professional-services contracts — no public pricing tiers are disclosed. Customer logos (Pacira BioSciences, Xgene Pharmaceutical, South Rampart Pharma, Small Pharma, Concentric) are concentrated in pain and CNS programs for mid-cap and small-cap sponsors. The company claims contributions to 32 FDA approvals since 2023 (27% of all US drug approvals) and more than 3,400 studies cumulatively with ERG, positioning itself as a high-throughput specialty CRO. Leadership is led by President Dr. William Martin (former Alkermes, Pfizer) and COO Lisa Cox, with no disclosed institutional investors; the firm is founder/management-owned under an LLC structure.

Name

Lotus Clinical Research

Legal name

Lotus Clinical Research, LLC

Website

https://lotuscr.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Lotus Clinical Research is a US-based specialty CRO providing full-service Phase I–IV clinical trial services for pharmaceutical and biotechnology sponsors, with deep expertise in CNS, pain, neurology, addiction, and metabolic indications, supported by an integrated site network via Evolution Research Group and proprietary scientific solutions including rater training, placebo response mitigation, and the NeuroKit CNS testing platform.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical research organization
• Contract research services
• Neuroscience clinical trials
• Metabolic clinical research
• Phase I clinical pharmacology

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Full-Service CRO Services: Comprehensive clinical research organization services including project management, clinical monitoring, medical monitoring, EDC & data management, biostatistics, PK/PD modeling, and quality operations. Revenue generated through professional services contracts with pharmaceutical and biotechnology sponsors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lotus Clinical Research is a full-service global Contract Research Organization (CRO) that runs neuroscience and metabolic clinical trials from first-in-human through late-phase development. The firm delivers project management, clinical monitoring, medical monitoring, EDC and data management, biostatistics, PK/PD modeling, and quality operations, complemented by proprietary scientific solutions such as Placebo Response Mitigation, Global Rater Training, and Unified Site Methodology. Through common ownership with Evolution Research Group (ERG), Lotus has priority access to 20 wholly-owned US research sites, 400+ beds, nine surgical centers, and dedicated Phase I units.

Product overview

Lotus Clinical Research operates as a global CRO (Contract Research Organization) offering a comprehensive, integrated suite of clinical trial services. The company is structured around core CRO services (Project Management, Clinical Monitoring, Medical Monitoring, EDC & Data Management, Biostatistics, PK/PD Modeling, and Quality Operations) complemented by specialized Scientific Solutions (Global Rater Training & Certification, Placebo Response Mitigation, Unified Site Methodology, Eligibility Review, Medical Writing, and Scientific Consultation). A key differentiator is the company's common ownership with Evolution Research Group (ERG), providing integrated access to a network of 20+ wholly-owned US research sites, 400+ beds, and dedicated Phase I units. The Summit Analytical division delivers specialized biostatistics and statistical programming, while the NeuroKit CNS testing platform (developed in partnership with CHDR) provides portable pharmacodynamic assessments. Services span Phase I through Phase IV trials across neuroscience (psychiatry, pain, neurology, addiction) and metabolic (obesity, diabetes, MASH) therapeutic areas, supported by a Scientific Leadership Team of 47 MDs and 12 PhDs/PsyDs.

Differentiator

Problem solved

Functional benefit

Brands

• Summit Analytical: A wholly-owned division of Lotus Clinical Research providing biostatistical support across the full development lifecycle from early-phase trials to post-marketing and real-world evidence studies.

Products and services

• Project Management Clinical trial project management services providing operational leadership, timeline management, risk mitigation, vendor coordination, and team communication. Project managers have average 10+ years industry tenure and act as extensions of sponsor teams.
• Clinical Monitoring
• Medical Monitoring
• EDC & Data Management
• Biostatistics & Summit Analytical
• PK/PD Modeling & Simulation
• Quality Operations
• Global Rater Training & Certification
• Placebo Response Mitigation (PRM)
• Unified Site Methodology (USM) Program
• Eligibility Review
• Medical Writing
• Clinical Development & Scientific Consultation
• NeuroKit CNS Testing Platform Portable CNS testing platform adapted from CHDR's NeuroCart system, providing high-quality standardized CNS assessments including adaptive tracking, body sway, N-back test, VAS scales, saccadic eye movement, and smooth pursuit eye movement for Phase I-IIa trials. Available exclusively in the US through Lotus and ERG.
• Phase I Clinical Pharmacology Units
• Renal & Hepatic Studies
• Biomarkers
• Cardiac Safety
• ERG Site Network

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Centre for Human Drug Research (CHDR)coreTechnology or Integration · 13 October 2025Exclusive US partnership to bring NeuroKit CNS testing platform to the US market. NeuroKit is adapted from CHDR's NeuroCart system and is available exclusively in the US through Lotus and ERG. Clinical Pharmacology of Miami (CPMI) is the first US site to deploy the platform.
• Veeva SystemscoreTechnology or Integration · 30 May 2023Expanded partnership using Veeva Vault Clinical Suite including Vault EDC, Vault CTMS, and Vault eTMF. The partnership enables substantial decrease in clinical trial startup time and improved operational efficiency across Lotus studies.
• Evolution Research Group (ERG)coreStrategic or Co-development PartnerCommon ownership partnership providing integrated CRO and site network services. ERG operates 20 wholly-owned US-based research sites with 400+ beds, nine surgical centers, and Phase I units. Lotus-Sponsor studies are prioritized within the ERG network. The collaboration enables rapid study startup and prioritized enrollment for Lotus clients.
• FNIH Biomarkers ConsortiumminorStrategic or Co-development PartnerERG holds membership in the FNIH Biomarkers Consortium with representation on the Metabolic Diseases Steering Committee. Subject matter experts contribute to supporting crucial development programs in metabolic diseases.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global full-service CRO and clinical technology vendor with deep CNS and metabolic capabilities. Lotus competes for the same enterprise pharma accounts on bundled full-service offerings, though IQVIA's breadth dwarfs Lotus' specialty focus.
• Fortrea (formerly LabCorp Drug Development): Top global full-service CRO spun out from LabCorp in 2023 with end-to-end Phase I-IV capabilities including CNS and metabolic therapeutic areas. Competes directly for mid- to large-pharma full-service outsourcing mandates.
• Parexel International: Top-5 global CRO with broad CNS and metabolic therapeutic expertise acquired through legacy and recent clinical operations build-out. Competes for the same large-pharma outsourced trial mandates.
• ICON plc: Largest pure-play global CRO (post-PRA merger) with full therapeutic-area coverage including CNS and metabolic. Competes with Lotus for large-pharma full-service Phase II-IV trials and biotech sponsor mandates.
• Syneos Health: Global biopharmaceutical services organization spanning clinical development and commercial—offers comparable full-service CNS/metabolic CRO capabilities at larger scale. Competes on enterprise pharma outsourcing relationships and global trial footprint.

Direct peers

• Worldwide Clinical Trials: Mid-sized specialty CRO with deep CNS, pain, and cardiometabolic expertise. Closest direct competitor to Lotus—competes for the same pharma/biotech sponsors running CNS and metabolic trials with comparable therapeutic-area focus and similar size/scale.
• Premier Research: Specialty CRO emphasizing CNS, oncology, and rare disease trials with similar full-service model (project management through biostatistics). Lotus competes head-to-head on CNS and metabolic RFPs; now owned by KCR/Croone.
• Clario: Major clinical trial technology and eCOA/ePRO vendor serving CNS and metabolic trials. Comparable function to Lotus' Veeva-integrated EDC/CTMS/eTMF stack and NeuroKit platform—competes on clinical trial informatics and endpoint data quality.
• Altasciences: Early-phase CRO with dedicated Phase I clinical pharmacology units and integrated preclinical-to-clinical services. Direct overlap with Lotus' Clinical Pharmacology of Miami and Ohio Clinical Trials Phase I units serving healthy volunteer and special population studies.

Emerging players

• Analgesic Solutions: Niche pain-CRO consultancy specializing in analgesic trial design, endpoint selection, and pain measurement—overlapping with Lotus' analgesic/pain trial focus (~600+ pain studies) and competing for the same sponsor pain franchise programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lotusclinicalresearch

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lotus Clinical Research